Nipro affiliate Spryte Medical completes enrollment in INSYTE pivotal nOCT aneurysm imaging trial

• Nipro affiliate Spryte Medical completed enrollment in the INSYTE US pivotal trial for its investigational nOCT Imaging System in brain aneurysm procedures.
• Enrollment reached 65 subjects in five months, led by 16 investigators across eight centers in three countries.
• Spryte is moving toward an FDA submission seeking an indication for use during endovascular treatment of intracranial aneurysms.
• The IDE study is assessing safety and the ability to generate high-resolution intravascular images during procedures and follow-up evaluation.
• The nOCT Imaging System remains investigational in the US and is not commercially available.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nipro Corporation published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.